CN108079119A - Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof - Google Patents

Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof Download PDF

Info

Publication number
CN108079119A
CN108079119A CN201711198221.4A CN201711198221A CN108079119A CN 108079119 A CN108079119 A CN 108079119A CN 201711198221 A CN201711198221 A CN 201711198221A CN 108079119 A CN108079119 A CN 108079119A
Authority
CN
China
Prior art keywords
parts
rutin
oral liquid
cardiovascular
cerebrovascular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711198221.4A
Other languages
Chinese (zh)
Inventor
付平国
刘文瑞
欧玉莲
王建买
付嫦娥
刘小军
欧召国
付玉香
李凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyang Huashengda Forestry Science And Technology Co Ltd
Original Assignee
Hengyang Huashengda Forestry Science And Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengyang Huashengda Forestry Science And Technology Co Ltd filed Critical Hengyang Huashengda Forestry Science And Technology Co Ltd
Priority to CN201711198221.4A priority Critical patent/CN108079119A/en
Publication of CN108079119A publication Critical patent/CN108079119A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/08—Mineral waters; Sea water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A61K36/195—Strobilanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease, in terms of weight fraction, including the following raw material：100 parts of rutin, 0.5 2 parts of chlorogenic acid, 0.05 0.10 parts of isatis root extract, 1,000 2000 parts of mineral water, 0.2 0.8 parts of yeast zinc, 0.05 0.10 parts of Stevioside, 0.001 0.005 parts of yeast chromium, 0.03 0.10 parts of Co-Q10,13 parts of Honegsukle flower P.E, 5 10 parts of Calyx Seu Fructus Physalis extract.The rutin oral liquid is adapted to：Hypertension, hyperlipidemia and insomniac, cardiac etc..

Description

Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof
Technical field
The invention belongs to technical field of traditional Chinese medicines, and in particular to a kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and its system Preparation Method.
Background technology
Nowadays, cardiovascular and cerebrovascular disease has become one of three big killers for threatening health of people, due to the side effect ratio of Western medicine It is larger, therefore raising in long-term treatment, Chinese medicine preparation often becomes first choice；Wherein using refined rutin as raw material drug very It is welcome by patient；According to statistics, current China town and country cardiovascular and cerebrovascular diseases occur as 1.2%~1.8%, and the death rate is one thousandth, For national cardiovascular disease number of the infected in 1,600,000 people or so, the occurrence cause of cardiovascular and cerebrovascular diseases is mainly hypertension, hyperlipidemia；From Rise 54% between 1979~1991,12 years, the age is bigger, the easier generation of cardiovascular and cerebrovascular disease, present China 60 years old with For upper old man more than 1.3 hundred million, China has been enter into aging society.Predicted according to the World Health Organization, the year two thousand twenty whole world 40~60 years old with On population will rise to medicine economy report on October 13rd, more than 1,200,000,000,1997 and the World Health Organization from current 7.4 hundred million In the number that on 2 17th, 1997 announce in Geneva；There is within 1994 40% to die of cardiovascular and cerebrovascular disease in whole death tolls Disease.
Rutin product has softening cardiovascular and cerebrovascular, decompression, lipid-loweringing, pre- anti-stroke, and norcholesterol, cholagogic are convenient, promote new The functions such as old metabolism, and capillary toughness can be enhanced, improve cerebrovascular function, it is evident in efficacy for treating hypertension, it is domestic Outer demand is very big；It is medicine-food two-purpose medicinal material as defined in the Ministry of Public Health, develops health food and functional food at home and abroad all has There is wide market, supply falls short of demand always for high-end product, possesses great development space.
The content of the invention
One of the objects of the present invention is to provide a kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease, the rutin oral liquids A variety of cardiovascular and cerebrovascular diseases can be treated.
The second object of the present invention is the preparation method for providing above-mentioned rutin oral liquid.
The rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease, in terms of parts by weight, including the following raw material：Rutin 100 Part, 0.5-2 parts of chlorogenic acid, 0.05-0.10 parts of isatis root extract, 0.2-0.8 parts of yeast zinc, 0.05-0.10 parts of Stevioside, ferment Female chromium 0.001-0.0005 parts, 0.03-0.10 parts of Co-Q10,1-3 parts of Honegsukle flower P.E, 5-10 parts of Calyx Seu Fructus Physalis extract, ore deposit 1000-2000 parts of spring.
Preferably, mineral water is Zhangjiajie mineral water.
Preferably, bauhinia leaf extract can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease 0.1-1 parts.
Preferably, 0.5-1.0 parts of carthamin can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease.
Preferably, root of red-rooted salvia phenolic acid 0.005- can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease 0.009 part, preferably root of red-rooted salvia phenolic acid B.
Preferably, Fructus lycii P.E can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease 0.001-0.005 parts and 0.5-1.5 parts of notoginseng total saponin.
Preferably, tangshenoside 0.005- can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease 0.009 part.
Preferably, panaquilon 0.005-0.01 can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease Part, 0.005-0.009 parts of ganoderma lucidum polysaccharide.
The preparation method of the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease, in turn includes the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）By the raw material mixing in addition to mineral water；It adds in mineral water and stirs 45-60 minutes up to rutin oral liquid.
Rutin oral liquid of the present invention is precipitated as normal phenomenon, using it is front upper and lower rock corkage it is ready-to-drink；Usage and dosage:Mouthful Clothes, a 10-20ml, 3 times a day.
Specific embodiment
Embodiment of the present invention is described in detail below in conjunction with example, but those skilled in the art will manage Solution, the following example is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.
Mineral water is Zhangjiajie mineral water in embodiment.
Embodiment 1
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1580g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g Co-Q10 0.04g Honegsukle flower P.Es 1.9g
Calyx Seu Fructus Physalis extract 6g.
Embodiment 2
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1580g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Co-Q10s 0.04g
6 parts of Honegsukle flower P.E 1.9097g Calyx Seu Fructus Physalis extracts.
Embodiment 3
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1570g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g carthamin 0.8g Co-Q10s 0.04g
Honegsukle flower P.E 1.9097g Calyx Seu Fructus Physalis extracts 6g.
Embodiment 4
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g Co-Q10 0.04g Honegsukle flower P.Es 1.9g
Root of red-rooted salvia phenolic acid 7mg Calyx Seu Fructus Physalis extracts 6g.
Embodiment 5
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g carthamin 0.8g Co-Q10s 0.04g
Honegsukle flower P.E 1.9g root of red-rooted salvia phenolic acid B 7mg Calyx Seu Fructus Physalis extracts 6g.
Embodiment 6
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1500g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Co-Q10s 0.04g
Honegsukle flower P.E 1.9g Calyx Seu Fructus Physalis extract 6g Fructus lycii P.Es 3mg
Notoginseng total saponin 1g.
Embodiment 7
Rutin 100g chlorogenic acid 1.5g isatis root extracts 0.09g
Mineral water 1400g yeast zinc 0.3g Steviosides 0.06g
Yeast chromium 0.004g bauhinia leaf extract 0.7g Co-Q10s 0.05g
Honegsukle flower P.E 1.9g Calyx Seu Fructus Physalis extract 6g Fructus lycii P.Es 4mg
Notoginseng total saponin 0.9g.
Embodiment 8
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1380g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Co-Q10s 0.04g
Honegsukle flower P.E 1.9g Calyx Seu Fructus Physalis extract 6g tangshenoside 7mg
Panaquilon's 7mg ganoderma lucidum polysaccharide 6mg.
Embodiment 9
Rutin 100g chlorogenic acid 1.1g isatis root extracts 0.05g
Mineral water 1500g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.004g bauhinia leaf extract 0.7g Co-Q10s 0.05g
Honegsukle flower P.E 1.8g Calyx Seu Fructus Physalis extract 7g tangshenoside 9mg
Panaquilon's 6mg ganoderma lucidum polysaccharide 5mg.
Embodiment 10
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1300g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Co-Q10s 0.04g
Honegsukle flower P.E 1.9g Calyx Seu Fructus Physalis extract 8g root of red-rooted salvia phenolic acid B 8mg
Tangshenoside 7mg Fructus lycii P.E 6mg notoginseng total saponins 7mg.
Embodiment 11
Rutin 100g chlorogenic acid 1.2g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.005g bauhinia leaf extract 0.4g Co-Q10s 0.03g
Honegsukle flower P.E 1.7g Calyx Seu Fructus Physalis extract 5g root of red-rooted salvia phenolic acid B 6mg tangshenoside 6mg
Fructus lycii P.E 8mg notoginseng total saponins 7mg.
The preparation method of the rutin oral liquid of above example includes the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）By the raw material mixing in addition to mineral water；It adds in mineral water and stirs 60 minutes up to rutin oral liquid.
Rutin oral liquid clinical effectiveness of the embodiment of the present invention is as follows：
Experimental method：
A groups:Hypertensive patient 110 is divided into 11 groups, and every group of 10 people, every group of patient takes the rutin mouthful of embodiment 1-11 respectively Liquid is taken, 3 times a day, each 10mL, 40 minutes warm boiled waters before meals, 30 days are 1 course for the treatment of, are taken 4 course for the treatment of.
B groups：Thrombolysis compares, and patient 120 is divided into 12 groups, every group of 10 people, every group of rutin for taking embodiment 1-11 respectively Oral liquid, western drug treatment（Control group）, 3 times a day, each 20mL, 40 minutes warm boiled waters, are treated for 30 days for 1 before meals Journey, two groups of patients are in age, gender, thrombosis position, the course of disease, clinical manifestation etc. comparing difference without conspicuousness.
Experimental result：
A groups:The preceding patient's diastolic pressure of medication is more than 180mmHg, and systolic pressure is more than 110mmHg, main suit's giddy, tinnitus, uncomfortable in chest, gas Short, insomnia, head Doppler show that blood vessel has Partial Blocking；After taking 5 course for the treatment of, blood pressure tends to be steady, and lives and recovers completely.
Take 4 course for the treatment of rear hypertensive patient the results are shown in Table 1.
1 hypertensive patient of table takes the therapeutic effect of rutin oral liquid
。
B groups：The evaluated severity of thrombosis patients is suitable before medication, and patient is in age, gender, thrombosis position, disease Journey, clinical manifestation etc. comparing difference are without conspicuousness；Drug of the present invention, without complication, has no haemorrhage during thrombolysis Shape occasionally has patient slight gastrointestinal reaction occur, disappears after giving anti symptom treatment.
The experimental result of thrombosis patients is shown in Table 2 after taking 50 days.
Table 2
。
From table 2 it can be seen that rutin oral liquid treatment group is evident in efficacy higher than western medicine group, rutin oral liquid thrombolysis is A kind of safely and effectively method.
More than content describes the basic principle and main feature of the present invention, and the present invention is not limited to the above embodiments, Without departing from the spirit and scope of the present invention, various changes and modifications of the present invention are possible, these changes and improvements are all It falls into scope of the claimed invention.

Claims (10)

1. a kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease, in terms of parts by weight, including the following raw material：100 parts of rutin, it is green 0.5-2 parts of ortho acid, 0.05-0.10 parts of isatis root extract, 0.2-0.8 parts of yeast zinc, 0.05-0.10 parts of Stevioside, yeast chromium 0.001-0.005 parts, 0.03-0.10 parts of Co-Q10,1-3 parts of Honegsukle flower P.E, 5-10 parts of Calyx Seu Fructus Physalis extract, mineral water 1000-2000 parts.
2. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that the rutin is ore deposit Spring is Zhangjiajie mineral water.
3. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add in cercis 0.1-1 parts of floral leaf extract.
4. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add in safflower 0.5-1.0 parts of glucoside.
5. according to the rutin oral liquid of the treatment cardiovascular and cerebrovascular disease of claim 1 or 4, it is characterised in that pellet can also be added in Join 0.005-0.009 parts of phenolic acid.
6. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that the root of red-rooted salvia phenolic acid For root of red-rooted salvia phenolic acid B.
7. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add in matrimony vine 0.5-1.5 parts of 0.001-0.005 parts of seed extract and notoginseng total saponin.
8. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add in Radix Codonopsis 0.005-0.009 parts of glucoside.
9. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add in ginseng 0.005-0.01 parts of glucoside, 0.005-0.009 parts of ganoderma lucidum polysaccharide.
10. the preparation method of the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that successively Include the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）By the raw material mixing in addition to mineral water；It adds in mineral water and stirs 45-60 minutes up to rutin oral liquid.
CN201711198221.4A 2017-11-25 2017-11-25 Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof Pending CN108079119A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711198221.4A CN108079119A (en) 2017-11-25 2017-11-25 Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711198221.4A CN108079119A (en) 2017-11-25 2017-11-25 Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof

Publications (1)

Publication Number Publication Date
CN108079119A true CN108079119A (en) 2018-05-29

Family

ID=62173003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711198221.4A Pending CN108079119A (en) 2017-11-25 2017-11-25 Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof

Country Status (1)

Country Link
CN (1) CN108079119A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931269A (en) * 2006-10-13 2007-03-21 深圳市生物谷科技有限公司 Rutin containing medicine composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931269A (en) * 2006-10-13 2007-03-21 深圳市生物谷科技有限公司 Rutin containing medicine composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
田洋: "槐米中芦丁的提取工艺研究进展", 《广州化工》 *

Similar Documents

Publication Publication Date Title
CN103027138A (en) Tea for enlivening spleens and production method of tea
CN101467673A (en) Compound ginseng health product and preparation method thereof
CN104147345B (en) A kind of Chinese medicine composition for treating cardiovascular autonomic neuropathy
CN106106907A (en) A kind of by the liver-protecting tea beverage prepared by leaf of Camellia nitidissima Chi
CN101810337A (en) Health food containing pseudo-ginseng and ganoderma lucidum and radix astragali
CN107661409A (en) A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof
CN101120977B (en) Medicine for treating tumor
CN107080240B (en) A kind of health food conditioner for alleviating qi depression to blood stasis and preparation method thereof
CN108079119A (en) Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof
CN102068520B (en) Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof
CN101524473B (en) Worm grass anticancer longevity pellet and preparation method thereof
CN107854567A (en) A kind of Quercetin traditional Chinese medicine oral liquid and preparation method thereof
CN107753645A (en) Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof
CN106511915A (en) Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis
CN102266481B (en) Chinese medicinal preparation for treating chronic cerebral circulation insufficiency
CN102274357B (en) Pharmaceutical composition for treating coronary arteriosclerotic heart disease and preparation method thereof
CN101612251B (en) Traditional Chinese medicine for treating primary liver cancer
CN106343413A (en) Health food for assisting reduction of blood glucose, blood pressure and blood lipid
CN101129431A (en) Traditional Chinese medicine composition for preventing and controlling cardiovascular disease and relative disease, method of preparing the same and application of the same
CN101091736A (en) Composition of Chinese traditional medicine for treating tumor, and preparation method
CN104173745A (en) Nourishing and body-building Mongolian medicine
CN102772665B (en) Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof
CN108042646A (en) Quercetin oral liquid and preparation method thereof
CN110960586B (en) Ant sleeping-aid capsule and its preparation method
CN108042599A (en) A kind of Quercetin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180529

WD01 Invention patent application deemed withdrawn after publication